Acadian Asset Management’s UroGen Pharma URGN Stock Holding History

Acadian Asset Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4,563	Closed	-$63K	–	1829
2023 Q3	$63K	Sell	4,563 -2,624	-37%	-$42.1K	﹤0.01%	1398
2023 Q2	$74K	Buy	7,187 +2,624	+58%	+$28.9K	﹤0.01%	1464
2023 Q1	$42K	Buy	+4,563	New	+$42K	﹤0.01%	1542
2018 Q2	–	Sell	-5,315	Closed	-$264K	–	1849
2018 Q1	$264K	Sell	5,315 -18,425	-78%	-$923K	﹤0.01%	1000
2017 Q4	$884K	Sell	23,740 -853	-3%	-$30.4K	﹤0.01%	712
2017 Q3	$775K	Buy	+24,593	New	+$543K	﹤0.01%	724

Other funds holding URGN

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Acadian Asset Management's URGN Position: Q4 2023 in Review

Acadian Asset Management sold out of UroGen Pharma (URGN) in Q4 2023, closing a stake of 4,563 shares — an estimated $63K sold.

Acadian Asset Management first reported a position in URGN in Q3 2017 and held it in 6 quarters. The position peaked at $884K in Q4 2017. 105 funds tracked by Wall St. Rank hold URGN as of Q4 2023.

Acadian Asset Management reported no remaining UroGen Pharma position as of Q4 2023 after selling out during the quarter.
Acadian Asset Management sold 4,563 UroGen Pharma shares in Q4 2023, an estimated $63K.
Acadian Asset Management first reported a position in UroGen Pharma in Q3 2017 and held it in 6 quarters.
Acadian Asset Management's UroGen Pharma position peaked at $884K in Q4 2017.
105 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2023.

Based on Acadian Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.